How to deal with constipation

Susan Allen outlines the causes of and treatments for constipation and discusses special groups pharmacists should consider

Constipation is a common complaint, with incidence estimated at 12–19 per cent.1 Constipation means different things to different populations, individual patients and health care professionals, so it can be difficult to define. One broad definition of constipation is the passage of hard stools less frequently than is normal. Many misconceptions surround bowel habits and what is normal, leading to misdiagnoses and overuse of laxatives. “Normal” can be anything from passing stools two or three times a day to two or three times a week. It is a change from the norm for the individual that is significant.

Cause

Constipation can be classed as primary (idiopathic) or secondary (induced by a specific condition [see Panel 1] or medicine [see Panel 2, p24]). In most cases there is no pathological cause. Many non-medical factors predispose to constipation. The most significant are:

- Inadequate fluid intake (the normal stool consists of about 70 per cent water and dehydration results in a hard stool that can be difficult to pass; dehydration can be exacerbated by drugs, such as diuretics)
- Inadequate dietary fibre (the average UK adult consumes 12g fibre daily — far less than the 18g recommended by the Department of Health)
- Dieting (eg, slimming diets can be low in fibre)

Identify knowledge gaps

1. Which drugs predispose to constipation as a side effect?
2. What affects choice of laxative?
3. What advice can be given to parents with constipated children?

Before reading on, think about how this article may help you to do your job better. The Royal Pharmaceutical Society’s areas of competence for pharmacists are listed in “Plan and record”, (available at: www.rpsgb.org/education). This article relates to “common disease states” (see appendix 4 of “Plan and record”).

- Changes in lifestyle (eg, eating different foods or at different times reduced physical activity)
- Suppressing the urge to defecate

Constipation is frequently experienced by pregnant women and older people (particularly those in institutional care). Increased incidence in older people is multifactorial and reasons include side effects of medicines, reduced mobility, reduced intake of fibre-rich food (eg, due to dental problems) and medical conditions. Constipation is an often overlooked aspect of patient care in acute settings and can become a significant problem if it does not receive necessary attention.

Symptoms

Common symptoms of constipation are difficulty passing stools, abdominal discomfort and abdominal distension. If untreated, constipation can lead to:

- Faecal impaction (when a large mass of faeces cannot be passed) and bowel obstruction (with potential to progress to bowel perforation)
- Faecal and urinary incontinence
- Urinary tract infection
- Rectal bleeding
- Anal fissures

Figure 1: the colon, the end part of the digestive system, is divided into four sections: the ascending, transverse, descending and sigmoid colon

Panel 1: Medical conditions predisposing to constipation

- Coeliac disease
- Depression
- Diabetes mellitus
- Gastrointestinal obstruction (eg, gastrointestinal carcinoma, ileus, ovarian or uterine tumours)
- Hypercalcaemia
- Hypokalaemia
- Hypothyroidism
- Irritable bowel syndrome
- Multiple sclerosis
- Parkinson’s disease
- Damage to pelvic floor muscles (eg, post childbirth)
Straining to defecate can cause haemorrhoids, fainting and cardiac irregularities. It can worsen gastro-oesophageal reflux and mobilise a deep vein thrombus.

**Diagnosis**

The key feature in diagnosing constipation is a change in bowel habit from the norm for the individual. Constipation can result from lodged faeces in any part of the large bowel, but this usually occurs in the sigmoid colon or rectum (see Figure 1, p23).

For chronic constipation, the Rome II diagnostic criteria for functional gastroduodenal disorders is sometimes used for diagnosis. It considers bowel habits over three months and includes such parameters as straining at defecation; lumpy, hard stools; sensations of tenesmus (a continuous feeling of needing to defecate) or blockage; fewer than three bowel movements weekly and the use of manual techniques (eg, digital evacuation) to facilitate defecation.

Patients describing constipation as a new symptom unattributable to changes in lifestyle, medication or diet, should be referred. Any of the following symptoms should also trigger referral:

- Constipation alternating with diarrhoea
- The presence of blood or slime, or both, with or in the stools
- Constipation accompanied by abdominal pain or vomiting
- Unintentional weight loss
- Tenesmus

Chronic constipation has been linked to an increased risk of colon and rectal cancer. However, a transient period of harder stools or reduced frequency of defecation is a low risk symptom for colorectal cancer.

**Treatment**

In 2005, a quarter of the prescriptions for gastrointestinal medicines in England were for laxatives, costing over £50m. (The Table gives an idea of the laxatives most commonly prescribed and the relative costs.) However, many constipation remedies are available over the counter. The aims of treatment are to:

- Restore normal frequency of defecation
- Achieve regular, comfortable defecation using the least number of drugs for the shortest time
- Avoid laxative dependence
- Relieve discomfort

In general, all patients benefit from dietary and lifestyle advice. A minimum of 18g and up to 30g fibre and 2L of fluid daily is recommended for adults. However, it should be noted that fluid increase is contraindicated in some people (eg, in heart or renal failure). Most people see benefits in three to five days, but it can take a month for a new fibre-rich diet to take full effect. Increased exercise is beneficial in constipation. Patients should also be encouraged to respond immediately to any urge to defecate. Failure to do so can result in

<table>
<thead>
<tr>
<th>Class</th>
<th>Examples</th>
<th>Time to effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bulking agents</td>
<td>Unprocessed bran</td>
<td>2–3 days</td>
</tr>
<tr>
<td></td>
<td>Ispaghula husk</td>
<td>2–3 days</td>
</tr>
<tr>
<td></td>
<td>Sterculia</td>
<td>2–3 days</td>
</tr>
<tr>
<td></td>
<td>Methylcellulose</td>
<td>2–3 days</td>
</tr>
<tr>
<td>Stimulant laxatives</td>
<td>Bisacodyl (oral)</td>
<td>10–12h</td>
</tr>
<tr>
<td></td>
<td>Bisacodyl (rectal)</td>
<td>20–60min</td>
</tr>
<tr>
<td></td>
<td>Senna</td>
<td>8–12h</td>
</tr>
<tr>
<td></td>
<td>Dantron in co-danthramer capsules (with poloxamer “188”)</td>
<td>6–12h</td>
</tr>
<tr>
<td></td>
<td>Dantron in co-danthrusate caps (with docusate sodium)</td>
<td>6–12h</td>
</tr>
<tr>
<td></td>
<td>Sodium picosulphate</td>
<td>10–14h</td>
</tr>
<tr>
<td>Faecal softeners</td>
<td>Docusate sodium (oral)</td>
<td>12–72h</td>
</tr>
<tr>
<td></td>
<td>Docusate sodium (rectal)</td>
<td>15–20min</td>
</tr>
<tr>
<td></td>
<td>Glycerol (suppository)</td>
<td>15–60min</td>
</tr>
<tr>
<td></td>
<td>Arachis oil (enema)</td>
<td>30min</td>
</tr>
<tr>
<td>Osmotic laxatives</td>
<td>Lactulose</td>
<td>Up to 2 days</td>
</tr>
<tr>
<td></td>
<td>Macrogol</td>
<td>1–3 days</td>
</tr>
<tr>
<td></td>
<td>Magnesium hydroxide BP</td>
<td>3–6h</td>
</tr>
<tr>
<td></td>
<td>Magnesium sulphate</td>
<td>2–4h</td>
</tr>
<tr>
<td></td>
<td>Phosphate (suppository)</td>
<td>30min</td>
</tr>
<tr>
<td></td>
<td>Phosphate (enema)</td>
<td>15min</td>
</tr>
<tr>
<td></td>
<td>Sodium citrate (microenema)</td>
<td>8–12h</td>
</tr>
</tbody>
</table>

Table: Number of NHS prescriptions and associated costs of commonly used laxatives in England 2005*

<table>
<thead>
<tr>
<th>Laxative</th>
<th>Number of prescriptions</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactulose</td>
<td>4,328,300</td>
<td>£13,030,200</td>
</tr>
<tr>
<td>Senna preparations</td>
<td>3,505,600</td>
<td>£6,002,700</td>
</tr>
<tr>
<td>Ispaghula husk</td>
<td>2,000,700</td>
<td>£8,123,900</td>
</tr>
<tr>
<td>Macrogol 3350</td>
<td>1,411,000</td>
<td>£12,014,400</td>
</tr>
<tr>
<td>Co-danthrusate</td>
<td>74,500</td>
<td>£915,500</td>
</tr>
</tbody>
</table>

* From Prescription Cost Analysis, 2005, The Information Centre
Laxatives are used when dietary measures are not feasible, when they have failed or while waiting for dietary measures to take effect. They are also useful in situations where straining to pass stools should be avoided (eg, angina, haemorrhoids), and in drug-induced constipation.

There are four main groups of laxatives: bulk-forming, stimulant, osmotic and faecal softening. There is limited evidence comparing the effectiveness of laxatives, so drug selection should be based on:

- **Patient preference**
- **How quickly an effect is needed** (see Panel 3)
- **Whether the stool is hard or soft**
- **Side effects**
- **Cost**

Where constipation is not induced by necessary drug therapy or chronic illness, the laxative should be used for a short time until dietary and lifestyle changes become effective.

**Bulk-forming laxatives** Bulk-forming laxatives (ispaghula husk, sterculia and methylcellulose, which is also a faecal softener) add mass to faeces to stimulate peristalsis. Bulk-forming laxatives are particularly useful if stools are small and hard. They take several days for full effect so are not suitable for immediate relief but can be used by patients with normal gut motility and uncomplicated constipation. They are also used long-term in patients who are prone to constipation. Proprietary ispaghula or sterculia granules should be mixed with water and taken immediately. Celevac (methylcellulose) is a tablet formulation. It is important to maintain good fluid intake with all bulk-forming laxatives to avoid intestinal obstruction.

Bulk-forming laxatives should not be taken just before going to bed. They commonly cause increased flatulence and abdominal bloating in the early stages of treatment, but these settle with time.

**Stimulant laxatives** Stimulant laxatives increase intestinal motility by direct stimulation of colonic nerves; they do not act on the small intestine (bisacodyl is an exception). Members of this group include senna (an anthranoid derived from plants), dantron (a synthetic anthranoid associated with bowel and liver tumours in animals and restricted to use in patients who are terminally ill), bisacodyl and sodium picosulfate (polyphe- 
nolics which are hydrolysed to the same active metabolite). Senna and bisacodyl are most commonly used short-term for acute constipation. They should be avoided where there is obstruction. Taken before going to bed, they produce a bowel movement the following morning. They can cause abdominal cramps and prolonged use should be avoided because they can cause diarrhoea and fluid and electrolyte imbalance. Bisacodyl suppositories can cause local inflammation and dantron can colour urine red.

**Osmotic softeners** Docusate sodium has some stimulant activity but is chiefly a faecal softener, lowering surface tension and allowing water to penetrate hard, dry faeces. It is combined with dantron in co-danthrusate for opioid-induced constipation in palliative care. Glycerol suppositories and arachis oil enema can be used rectally to soften impacted faeces. Arachis oil should not be used by people who are allergic to nuts. Liquid paraffin is no longer recommended.

### Panel 4: Constipation in children

Constipation is common in childhood and the diagnostic criteria are different from those for adults. In an infant or preschool child, constipation can be diagnosed if, for two weeks or more, the child has pebble-like hard stools most of the time or firm hard stools fewer than three times a week. There should be no evidence of structural, endocrine or metabolic disease. Faecal retention can be diagnosed in a child up to 16 years of age when, for at least 12 weeks, there has been passage of large volume stools less than twice a week and retentive posturing (crossing the legs and squeezing the buttocks) to avoid defecation.

Many conditions predispose children to constipation, including attention deficit hyperactivity disorder, autism, coeliac disease, cystic fibrosis, dehydration, metabolic conditions, spinal cord abnormalities and cerebral palsy. In addition, constipation may have a psychological cause. For example, pain precipitated by the passage of an uncomfortable stool can cause the child to resist bowel movements in the future. In a child with no underlying medical condition there can be anxieties surrounding potty training or starting school, causing the child to resist the urge to defecate. Frequently, dietary factors are involved.

When constipation starts in infancy, serious underlying disease is unlikely. This does not apply to newborn babies, where investigation is needed.) Up to six months of age, babies are recommended to receive only breast or formula milk. Breast-fed infants are rarely constipated. For bottle-fed babies, checking that formula feeds are made according to directions, and not over concentrated, is useful. After six months, solids are introduced with gradual inclusion of vegetables, fruits and water. From two to five years of age, a child’s diet should move towards that of an adult, and by five years old, it should include five portions of fruit or vegetables daily (although in smaller portions). For toddlers, advice to increase consumption of water, fresh fruit juice with meals (to avoid dental caries), cooked and raw fruit and vegetables, can help constipation. Toddlers drinking large amounts of cows’ milk may be prone to constipation (or diarrhoea). Milk can reduce appetite for fibre-rich foods.

Use of laxatives in children should be discouraged, but after dietary measures, they may be used daily for up to two years, under medical supervision or on the advice of a health visitor, to establish soft stools that can be passed without discomfort. Once regular bowel function is restored, laxatives can be gradually withdrawn over several months. There is a suggestion that bulk or osmotic laxatives should be tried first and stimulant laxatives or a combination approach tried if this fails. The stool-softening properties of docusate sodium may help children with megarectum (where rectal accumulation of bulky stools over time causes an enlarged rectum and decreased rectal sensation).

### Panel 5: Constipation in pregnancy

Constipation affects around 38 per cent of pregnant women, largely due to increased progesterone levels reducing intestinal motility and increasing gut transit time. Other factors can include nausea and vomiting in early pregnancy (causing changes to diet and dehydration), iron supplements, pressure on the bowel from the growing baby and reduced physical activity. Dietary modifications and exercise may be all that is needed. If laxatives are necessary, agents that are poorly absorbed from the gastrointestinal tract are preferred (eg, bulk forming, faecal softening and osmotic agents). Senna can be given if other measures fail, but must be used with caution in the third trimester because it can induce uterine contractions.

Susan Allen, PgD (Comm), MRPharmS, is a freelance pharmaceutical and copy writer from Market Harborough.
Panel 6: Constipation in cancer

Reduced volume and frequency of defecation is expected in people who are terminally ill. Most palliative care patients require a laxative because of medication with opioids, gastrointestinal obstruction or neurological problems. Additional aggravating factors include hypercalcaemia, treatment with cytotoxics, depression (and associated drug treatment), reduced mobility, nausea, dehydration and reduced fibre intake.

Tolerance to opioid-induced constipation does not develop, so co-prescribing laxatives from the outset is encouraged. Some opiates are more constipating than others (e.g. morphine more so, fentanyl less so). Where appropriate, patients should be encouraged to consume fibre-rich foods (e.g. fruit juice and stewed fruit) and maintain a good fluid intake. Laxative treatment usually requires both a stool softener and a stimulant laxative (commonly co-danthrusate) to maintain normal bowel movements. Osmotic laxatives are often given to those intolerant to stimulant laxatives. 

For opioid-induced constipation, laxative doses are frequently higher than stated in the BNF. Prokinetic agents, such as metoclopramide, can help with delayed gastric emptying. About a third of patients need rectal measures (e.g. enemas, manual evacuation) to manage constipation.

Osmotic laxatives

Osmotic laxatives work within the colonic lumen to retain and draw water into the intestine by osmosis. Lactulose, macrogols, magnesium salts, phosphates and sodium salts fall into this group. Lactulose is a semi-synthetic disaccharide (galactose and fructose combined). It is not absorbed from the gastrointestinal tract, so it can be used by people with diabetes. It takes two to three days to take effect so will not give immediate relief. Side effects are flatulence and abdominal discomfort.

Macrogol powders (polymers of ethylene glycol) have shown some benefits over lactulose in small, short-term trials. They can be more effective in increasing stool frequency and reducing straining over four weeks and may be less likely to cause flatulence. However, macrogol powders may be more likely to produce liquid stools. By nature of their action, osmotic laxatives need to be accompanied by good fluid intake.

Magnesium hydroxide is purgative and can be abused, but occasional use is acceptable. Magnesium sulphate is sometimes used when rapid bowel evacuation is needed. Again this is not suitable for regular use.

Suppositories and enemas

Suppositories and enemas can be used when oral laxatives are ineffective or there is impaction low down in the gastrointestinal tract. Choice of product depends on the site of impaction and the type of stools. Relatively soft rectal faeces respond to bisacodyl suppositories provided there are no haemorrhoids or anal fissures. Hard rectal stools may be treated with glycerol suppositories which are hygroscopic, lubricant, and have some stimulant activity.

For more severe impaction a softening enema, such as docucate sodium or arachis oil, can be used overnight followed by a phosphate enema (osmotic laxative) the following morning. Enemas are not intended for regular use, but may need to be repeated several times to clear impacted faeces. Basic tips that pharmacists can give for enema use include:

- Warm the enema to body temperature (e.g. using a jug of warm water)
- Lubricate the nozzle with lubricating jelly or white soft paraffin to ease insertion
- Use a towel to lie on
- The patient should lie on his or her side, with knees drawn up
- The tube length selected (long or short) depends on patient (or carer) preference for ease of use and does not affect nozzle positioning in the rectum
- Hold the enema above the upper hip can aid administration
- After administration, sphincter muscles should be squeezed for a few minutes to stop the liquid running out

Herbal laxatives

Plant extract laxatives are either bulk-forming (e.g. psyllium, linseed, fenugreek) or stimulant (e.g. senna leaves, cascara bark, aloes, buckthorn and rhubarb). Evidence comparing herbal agents with conventional laxatives is lacking, and the British National Formulary recommends herbal laxatives are avoided because their action is unpredictable. They are, however, sold in some pharmacies and may be requested by customers. Cautions for use apply as with conventional preparations.

Special considerations

As mentioned, some people (e.g. pregnant women and the terminally ill) are more prone to constipation. In addition, constipation in children requires special consideration. These groups are discussed in Panels 4, 5 (p25) and 6.

Laxative misuse and eating disorders

Laxatives are listed as potential substances of misuse in the Royal Pharmaceutical Society's practice guidelines. Misuse can occur in those with eating disorders, such as anorexia, but also in normal or overweight individuals. Laxative misuse in the U.K. has been reported at 2 per cent in secondary school students and 13 per cent in college students. Pharmacists need to be aware and ready to advise those buying laxatives repeatedly and excessively, and direct customers to support agencies.

References

Resources

- www.dh.gov.uk contains information on constipation and the risk factors for cancer
- www.eatwell.gov.uk contains information on healthy eating
- www.radcliffe-oxford.com/books/samplechapter/5111/01_PCF2-396c9b9d2ef0d.pdf contains information on constipation in palliative care